The pitch sounds almost too neat: Take raw hospital data—the messy stuff buried in electronic health records, scribbled clinical notes, grainy echocardiogram videos—and transform it into something pharmaceutical companies will actually pay for. Something that might, if Dandelion Health's founders are right, upend how drugs get developed.
On May 5, 2026, the New York-based startup announced it had raised $14 million in Series A funding, led by Healthier Capital, the healthcare-focused fund started by Amir Dan Rubin. You might remember Rubin as the CEO who steered One Medical to its 2020 IPO before Amazon acquired it in early 2023. Now he's betting that clinical data infrastructure—not exactly the sexiest corner of health tech—represents the next big unlock for an industry drowning in information but starved for insight.
The investment comes as Dandelion says its network has swelled to 73 hospitals serving more than 15 million patients. That's up considerably from the 10 million patient records across just three hospital partners when the company secured its $15.889 million seed round back in December 2023, led by Primary Venture Partners.
"The combination of large-scale real-world data with raw biological signals creates unprecedented opportunities for drug development and AI validation," Aman Mahajan, a physician and partner at Healthier Capital, said in a statement. The fund, which closed its first $220 million vehicle in January, joined existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures in the round. Colle Capital also participated.
The Aggregation Play
Founded in 2020, Dandelion has been quietly building what it describes as a multimodal clinical intelligence platform—corporate speak for a system that pulls together wildly different types of medical information. We're talking structured electronic health records sitting alongside unstructured clinical notes, medical imaging, ECG readings, radiology scans, pulmonary function tests. All told, the company says it manages over 8 petabytes of patient data, though verifying such figures from the outside remains difficult.
The company's software suite includes tools with names like Precision Trial Designer and Evidence Explorer, products aimed at helping life sciences companies and AI developers do everything from optimizing clinical trials to discovering biomarkers. Dandelion also runs the American Heart Association AI Assessment Lab, which conducts independent assessments of cardiology and stroke AI tools.
Hospital partners now include Sharp HealthCare, Sanford Health, and Montefiore Einstein, the latter of which joined the consortium last October.
The Economics Argument
Here's where things get interesting, or at least where Dandelion wants them to get interesting. The company points to a trial emulation project with what it describes as a top-10 pharmaceutical company—name undisclosed—that it claims could deliver up to $84 million in cost savings and shave as much as 11 months off conventional trial timelines.
Those are eye-catching numbers. They're also the company's own projections, without independent verification, and Dandelion didn't offer much detail on the methodology behind them. Still, the promise of faster, cheaper drug trials has proven irresistible to investors in recent years, particularly as AI hype has swept through healthcare.
The broader context here matters. Digital health funding has been consolidating into fewer, larger deals—Rock Health reported that $4 billion flowed into just 110 deals during the first quarter of this year. AI capabilities, once a differentiator, now feel more like table stakes. Everyone claims to have them.
And regulators seem to be leaning in. The FDA launched a pilot program in April for real-time AI monitoring of certain clinical trials, a development that could accelerate adoption of the kind of infrastructure Dandelion is building. Whether that regulatory tailwind translates into commercial traction remains an open question.
What Comes Next
Dandelion plans to use the fresh capital to expand pharmaceutical partnerships, scale its data and engineering infrastructure, and grow its commercial and scientific teams. Standard playbook stuff for a Series A.
The founding team brings some pedigree: Elliott Green, the CEO, previously worked as VP of partnerships and strategy at Oscar Health. Ziad Obermeyer, the chief scientific officer, holds a faculty position at UC Berkeley. MIT economist Sendhil Mullainathan serves as a scientific advisor, while Niyum Gandhi, CFO of Mass General Brigham, chairs the board.
Whether Dandelion can execute on its trial disruption thesis—turning hospitals' messy data exhaust into pharma's next competitive advantage—will depend on factors well beyond capital raising. Integration challenges, data privacy concerns, and the notoriously slow pace of pharma decision-making all loom large.
But for now, at least, Rubin and his fellow investors are betting that the answer lies somewhere in those 8 petabytes of clinical noise. Perhaps there's signal in there after all.
